drugset / Trial / NCT02849951
A Study to Investigate the Safety and Efficacy of LT-02 in Patients With Mesalamine Refractory Ulcerative Colitis (UC)
Phase 3
Terminated
25 enrolled
Prometheus Laboratories
Nestlé Health Science Spain · collabSyneos Health · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this study is to determine whether Phosphatidylcholine (LT-02) add on treatment is effective and safe for the induction of remission in ulcerative colitis patients refractory to standard treatment with mesalamine
Timeline
- Start
- 2016-07
- Primary completion
- 2019-03
- Completion
- 2019-08
Outcome
Outcome not reported
Stopped: “LT-02 did not appear to help induce remission of UC”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | LT-02 | Unknown | 1.6 g | Oral |